Vanguard Group Inc Pacira Bio Sciences, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,298,683 shares of PCRX stock, worth $101 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,298,683
Previous 5,084,831
4.21%
Holding current value
$101 Million
Previous $145 Million
45.15%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$152 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$94.2 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$38.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$37.6 Million0.05% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.96MShares$37.1 Million0.03% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $870M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...